Immunotherapy combination improves response in unresectable melanoma

Source: Healio, August 2024

An immunotherapy combination improved outcomes compared with historical control for certain patients with advanced melanoma, according to a topline data announcement.

BNT111 (BioNTech) — an investigational immunotherapy — uses a fixed combination of mRNA-encoded, tumor-associated antigens designed to activate a precise and strong immune response against cancer.

The randomized phase 2 BNT111-01 trial included patients with anti-PD-1/PD-L1-refractory or relapsed unresectable stage III or stage IV cutaneous melanoma.
READ THE ORIGINAL FULL ARTICLE